Drug Type Chemical drugs |
Synonyms CTS 3497, CTS3497 |
Target |
Action inhibitors |
Mechanism PRMT5 inhibitors(Protein arginine methyltransferase 5 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Malignant Solid Neoplasm | Phase 2 | China | 25 Dec 2024 | |
Lymphoma | Phase 2 | China | 24 Dec 2024 | |
Methylthioadenosine phosphorylase deletion cancer | Phase 2 | China | 24 Dec 2024 | |
Esophageal Carcinoma | Phase 1 | China | - | |
Non-Small Cell Lung Cancer | Phase 1 | China | - | |
Pancreatic Cancer | Phase 1 | China | - | |
Advanced Lymphoma | IND Approval | China | 27 Nov 2024 | |
Esophageal Squamous Cell Carcinoma | Preclinical | China | 17 Apr 2024 |